Teplizumab, a new drug, could delay the need for insulin for patients with type 1 diabetes by up to 3 years.
Călin Nicolescu
Health
Foto Pixabay
Always see our news on Google
Teplizumab, a drug already approved in the US, is being tested in the UK to slow the progression of type 1 diabetes by training the immune system to protect pancreatic cells. Hannah Robinson, the first British adult to receive the treatment, hopes it will delay the need for insulin. Experts believe the treatment represents a major change in diabetes management, with the potential to alter the immune process and help high-risk people avoid insulin therapy.
Sources
Un medicament "revoluţionar" ar putea încetini evoluţia diabetului de tip 1. Poate întârzia nevoia de insulină cu 3 ani
Devon mother treated with game-changing diabetes drug
Mother of two becomes the first UK patient to receive ‘groundbreaking’ new diabetes drug
Un medicament „revoluționar”, o nouă speranță pentru diabetul de tip 1. Ce așteptări au medicii
Latest News
07:22
NATO strengthens the eastern flank. Spain is sending seven F-18 fighter jets, three drone-equipped helicopters, and 200 soldiers to the Kogălniceanu base.
07:21
Trump announces an agreement for the disarmament of Hamas and the gradual withdrawal of Israel from Gaza
07:06
CFR Cluj has saved the honor of Romanian teams in the Conference League
23:00
Claudiu Manda, the general secretary of the PSD, accuses Prime Minister Ilie Bolojan of lying and responsibility for the crisis in the healthcare system.
22:45
Ben Affleck won 1 million dollars on "Do You Want to Be a Millionaire?" The money will be donated.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
